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The impact of lymphatic micrometastases on prognosis of non-small-cell ung 
cancer has not been clearly established. We therefore prospectively assessed the 
frequency, mode of mediastinal spread, and prognostic significance of lymphatic 
micrometastases in lymph nodes of 93 patients with completely resected non- 
small-cell lung cancer staged as pT1 to pT4 pN0 and pN1 by conventional 
histopathologlc techniques. Frozen tissue sections from 471 lymph nodes that were 
staged as free of metastases by routine histopathologic examination were screened 
for micrometastases by the alkaline phosphatase-antialkaline phosphatase immu- 
nostaining technique with the monoclonal antibody Ber-Ep-4. Twenty of 73 
patients (27.4%) with disease staged as pN0 and nine of 20 patients (45.0%) with 
disease staged as pN1 had nodal micrometastases. Eight of 17 patients with upper 
lobe primary tumors and five of 12 patients with lower lobe primary tumors 
exhibited skip micrometastases. Mean relapse-free survival was significantly 
increased in patients with pN0 disease without micrometastases (41.1 vs 29 
months, p = 0.0081). In patients with pN1 disease, mean relapse-free and 
cancer-related survivals were also significantly increased if no micrometastases 
were found (34.8 and 38.2 months vs 18 and 23.5 months, p = 0.0157 and p = 
0.0094). Patients with disease staged as pN0 and pN1 with micrometastases 
revealed no difference in cancer-related survival compared with a control popula- 
tion of patients with disease staged as pN2. The mode of spread was erratic. The 
prognosis of patients after upstaging of pN0 and pN1 disease according to results 
of immunohistochemical staining correlated strongly with the prognosis of pa- 
tients whose disease was staged at the higher stages by conventional histopatho- 
logic examination. These findings could represent a new indication for adjuvant 
therapy, supporting extensive lymph node sampling for staging purposes. 
(J Thorac Cardiovasc Surg 1996;112:623-30) 
M ediastinal lymph node involvement in non- 
small-cell lung cancer is a crucial factor in 
prognosis. Even patients with negative lymph nodes 
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and pT1 or pT2 lesions, however, have a 40% 
chance of recurrent disease within the first 2 years 
after an intended curative operation.l' 2 Early micro- 
metastatic tumor spread not detectable by current 
preoperative staging procedures and histopatho- 
logic examination must therefore be assumed. 
Recently, the specific detection of individual epi- 
thelial tumor cells in bone marrow and lymph nodes 
by immunocytochemical and histochemical assay 
employing monoclonal antibodies became possi- 
ble. 3-6 The evaluation of bone marrow provides 
information about systemic tumor cell dissemina- 
tion. Regional tumor cell dissemination is immuno- 
histochemically assessed by screening for microme- 
tastases in lymph nodes that are missed by routine 
histopathologic examination. 7 The conjunction of 
radical systematic lymphadenectomy with this im- 
munohistochemical staining method should lead to 
an accurate description of mediastinal spread and to 
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evaluation of the early stage of lymphogenic metas- 
tasis in bronchogenic carcinoma. We therefore per- 
formed a prospective study to assess frequency, 
mode of mediastinal spread, and prognostic signifi- 
cance of lymphatic micrometastases in lymph nodes 
of patients with completely resected non-small-cell 
lung cancer and no conventional histologic evidence 
of mediastinal nodal disease. 
Patients and methods 
This study was approved by the ethics committee of the 
University of Munich. 
Patients. Lymph nodes and tumor samples were col- 
lected from 129 patients with operable non-small-cell lung 
cancer treated by lobectomy or pneumonectomy in com- 
bination with mediastinal lymphadenectomy, as described 
elsewhere, 8 between October 1989 and December 1991. 
Informed consent was obtained from all patients before 
their inclusion in the study. Ninety-three patients with 
disease staged by postoperative histopathologic and clin- 
ical examination as without evident metastasis to the N2 
region (pT1 to pT4, pN0 and pN1, pM0, R0) were 
identified and represent the population for this study. The 
remaining 36 patients with lymph node involvement of 
mediastinal nodes (pN2 disease) were used as control 
group. Tumor stage and grading were classified according 
to the 4th edition of the TNM classification of the 
International Union Against Cancer? Patients were ex- 
cluded if they had evidence of intrapulmonary metastases 
or if the resected specimen exhibited residual tumor at the 
resection margin. Patients whose tumors were subse- 
quently classified as small-cell lung cancer were also 
excluded. 
After primary operation, patients were reexamined 
every 3 months for 2 years and thereafter at 6-month 
intervals. The evaluation included physical examination, 
plain chest radiography, bronchoscopy, computed tomog- 
raphy of the chest, abdominal ultrasonography, and bone 
scan. 
Histopathologic analysis and tissue preparation. At 
primary operation, lymph nodes of the ipsilateral thoracic 
cavity were removed by mediastinal lymphadenectomy 
and mapped by the surgeon according to the mapping 
scheme of the American Thoracic Society. 1° 
All resected lymph nodes were divided into two parts. 
One part was embedded in paraffin for routine his- 
topathologic staging (hematoxylin-eosin tain [HE]): the 
other part and a representative sample of the primary 
tumor were snap-frozen i  liquid nitrogen within 3 hours 
after removal and stored at -80°C until use. Lymph 
nodes from patients who had no evidence of nodal 
metastases of the N2 region (mediastinal lymph nodes) by 
routine histopathologic analysis were screened by means 
of immunohistochemistry. We used the antiepithelial 
monoclonal antibody Ber-Ep-4 (immunoglobulin G1), 
which is commercially available (Dako, Hamburg, Ger- 
many) and can be used on snap-frozen and paraffin- 
embedded material for the detection of micrometastatic 
tumor cells as described elsewhere. 7 Briefly, Ber-Ep-4 is 
directed against wo glycopolypeptides of 34 and 49 kd 
present on the surface and in the cytoplasm of all epithe- 
lial cells, except for the superficial ayers of squamous 
epithelia, hepatocytes, and parietal cells. The antibody 
does not react with mesenchymal tissue, including lym- 
phoid tissue, and can also be used on paraffin-fixed TM 12 
sections. 
From each lymph node, 4 to 6 txm sections were cut by 
cryostat from three different levels and transferred onto 
glass slides pretreated with 3-triethoxysilyl-propylamin 
(Merck, Darmstadt, Germany). One section per level was 
stained with the alkaline phosphatase-antialkaline phos- 
phatase technique. Briefly, cryostat-cut sections were fixed 
in acetone for 10 minutes at room temperature, air-dried, 
rehydrated, and preincubated with antibody-serum com- 
plex (diluted 1:10 with tris-phosphatase buffered saline 
solution) for 20 minutes to block unspecific bindings. The 
primary monoclonal antibody in appropriate dilution with 
antibody-serum complex (diluted 1:10 with tris-phos- 
phatase buffered saline solution) was applied for 45 
minutes at room temperature. After each incubation, 
repeated washings in tris-phosphatase buffered saline 
solution (three times for 5 minutes each) were performed. 
Subsequently, a rabbit-antimouse immunoglobulin G 
(Dako) was applied for 30 minutes, followed by the 
alkaline phosphatase-antialkaline phosphatase complex 
for another 30 minutes. Antibody-bound alkaline phos- 
phatase activity was detected with Fast Red TI" (Sigma, 
Deisenhofen, Germany); endogenous alkaline phos- 
phatase was quenched by addition of levamisole. After 
incubation for 10 to 15 minutes, cells were counterstained 
with Mayer's hemalum and mounted with Kaiser's glycer- 
inated gelatin. 
The specificity of this method had been previously 
evaluated by our group with lymph nodes from control 
patients with nonepithelial tumors or inflammatory dis- 
eases] The sensitivity of Ber-Ep-4 was determined as 99% 
by staining of cryostat-cut sections of primary tumor 
samples. 7 Sections of normal colon mucosa served as 
positive control preparations. Isotype-matched, irrelevant 
murine monoclonal antibodies erved as negative control 
preparations (MOPC 21 or immunoglobin G1; Sigma). To 
evaluate the effectiveness of immunostaining in compari- 
son with HE staining, adjacent sections of Ber-Ep-4- 
positive sections were stained with HE. Tumor cells could 
be detected by HE staining in none of these control 
sections (Fig. 1). 
A nodal micrometastasis in a given lymph node found 
to be tumor free by routine histopathologic staining was 
defined as the presence of single cells with positive 
Ber-Ep-4 staining or a cluster of cells with positive 
Ber-Ep-4 staining with a size of not more than 2 mm 
within the body of the lymph node (Fig. 1). Multiple 
micrometastatic lymph nodes within one level were con- 
sidered to represent one metastatic focus. Patients were 
excluded from analysis if immunohistochemical and his- 
topathologic reexamination revealed nodal metastases 
larger than 2 mm. 
For analysis of the mode of micrometastatic nodal 
spread to the mediastinum, patients were divided into 
four groups according to the location of the primary 
tumor. One group had right upper lobe primary tumors, 
one group had right middle or lower lobe primary tumors, 
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one group had left upper lobe primary tumors, and one 
group had left lower lobe primary tumors. 
The mediastinal nodes were separated into two regions, 
the upper and lower mediastinum. The upper mediasti- 
num contained node levels 1 through 4 on the right side 
and node levels l through 6 on the left side. The lower 
mediastinum contained node levels 7 through 9. Locore- 
gional nodes comprised node levels 10 through 14 (N1 
region). 
If the primary lesion was located in the upper lobe, the 
upper mediastinum was designated as the regional medi- 
astinum and the lower m diastinum was designated as the 
nonregional mediastinum. In lower-lobe lesions, the lower 
mediastinum was designated as the regional mediastinum 
and the upper mediastinum was designated as the nonre- 
gional mediastinum. 13 
Statistical analysis. Differences in the relative fre- 
quency of nodal micrometastases were compared by )(2 
test with Yates's correction. Recurrence-free, distant me- 
tastasis-free interval, cancer-related survival, and relapse- 
free survival were calculated with the Kaplan-Meier 
method. Log-rank tests were used for comparison of 
Kaplan-Meier-curves. The Cox proportional-hazards 
model was applied for multivariate analysis. For this 
analysis, all variables were dichotomized. The level of 
significance was set to a p value of less than 0.05. 
Results 
Patient characteristics. There were 95 patients 
whose primary tumors were initially classified as pT1 
to pT4 and pN0 to pN1. Two patients were excluded 
from analysis because histopathologic reexamina- 
tion and repeated immunohistochemistry revealed 
gross nodal metastases larger than 2 mm in size in 
the N2 region. Of the eligible patient population, 84 
were available for follow-up analysis. 
The mean age was 60 years, with a range of 38 to 
80 years. Primary tumors were located in the right 
upper lobe in 29 cases (31.3%), in the left upper 
lobe in 29 cases (31.3%), in the right middle or 
lower lobe in 19 cases (20.4%), and in the left lower 
lobe in 16 cases (17.2%). Tumors were typed and 
staged as depicted in Table I. 
Incidence of nodal micrometastases. Application 
of the immunohistochemical assay to cryostat-cut 
sections of 471 lymph nodes from 93 patients whose 
disease was staged by conventional histopathologic 
examination as pN0 or pN1 showed single cells or 
cell clusters 2 mm size or smaller with positive 
Ber-Ep-4 staining in 38 nodes (8.1%) in 29 patients 
(31.2%; Fig. 1). Twenty of 73 patients (27.4%) with 
disease staged as pN0 had nodal micrometastases, 
versus nine of 20 patients (45.0%) with stage pN1 
disease (not significant). Only one node level was 
affected in 21 patients, and two node levels were 
affected in seven patients. One patient exhibited 
Fig. 1. A, Micrometastasis in a histopathologically nega- 
tive lymph node detected with the monoclonal antibody 
Ber-Ep4. B, Adjacent section stained with HE does not 
reveal tumor cells. 
micrometastatic foci at three node levels. Fifteen 
patients had as many as three disseminated cells in 
the body of the nodes, eight additional patients had 
cell clusters of between four and 200 cells, and one 
patient exhibited a micrometastatic focus 2 mm in 
size. 
Effect of histologic type on extent of mediastinal 
nodal micrometastasis. Of 42 patients with adeno- 
carcinoma, 13 patients had one-level metastases, 
one had two-level metastases, and one patient ex- 
hibited three-level metastases. Of the 40 patients 
with squamous cell carcinoma, seven patients had 
one-level metastases and five patients had two-level 
metastases (not significant). 
Effect of primary tumor location on skip medias- 
tinal nodal micrometastasis. Table I I  shows the 
relationship between location of the primary tumor 
and prevalence of skip mediastinal nodal microme- 
tastasis. 
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Table I. Patient and tumor characteristics of 129 
patients with non-small-cell lung cancer 
pNO, pN1 pN2 
n % n % 
Sex 
male 68 73 27 75 
female 25 27 9 25 
Tumor type 
Adenocarcinoma 42 45.2 13 36 
Squamous cell carcinoma 40 43 16 44 
Adenosquamous carcinoma 3 3.2 2 6 
Large-cell carcinoma 8 8.6 5 14 
Tumor stage 
Stage I 66 71 0 0 
Stage II 13 14 0 0 
Stage IIIa 12 12.8 33 92 
Stage IIIb 2 2.2 3 8 
T stage 
T1 21 22.5 2 6 
T2 58 62.4 27 75 
T3 13 14 4 11 
T4 1 1.1 3 8 
N stage 
NO 73 78.5 0 0 
N1 20 21.5 0 0 
N2 0 0 36 100 
Age ranged from 38 to 80 years, with a mean of 60 years. 
Skip micrometastases were defined as metastatic 
foci in the nonregional mediastinum without in- 
volvement of the regional mediastinum or meta- 
static foci in the regional or nonregional mediasti- 
hum without metastases in locoregional nodes. 
Eight of 17 patients with primary tumors of the 
upper lobe exhibited skip metastases, versus five of 
12 patients with primary tumors of the lower lobe 
(not significant). 
Effect of micrometastases on survival 
Relapse-free and overall cancer-related survival Among 
the 67 patients available for follow-up with a his- 
topathologic nodal stage of NO, 51 patients had 
disease classified without nodal micrometastases by 
our immunohistochemical assay. Their mean re- 
lapse-free survival and cancer-related survival were 
41.1 months and 44.6 months, respectively. For the 
16 patients with nodal micrometastases, the mean 
relapse-free survival and cancer-related survival 
were 29.0 months and 36.5 months, respectively 
(p = 0.0081, p = 0.0584; Fig. 2; Table III). Patients 
with histopathologic stage N1 disease without fur- 
ther nodal micrometastases (n = 11) exhibited mean 
relapse-free survival of 34.8 months and cancer- 
related survival of 38.2 months, compared with six 
Table !I. Location of primary tumor and skip 
nodal micrometastases 
Primary tumor site No skip metastases Skip metastases 
NO group 
RUE (n = 6) 2 4 
LUL (n = 5) 4 1 
RMLL (n = 4) 2 2 
LLL (n = 5) 2 3 
N1 group 
RUL (n = 4) 2 3 
LUL (n = 2) 1 1 
RMLL (n = 2) 2 0 
LLL (n = 1) 1 0 
Skip metastases were defined as metastatic foci in the nonregional 
mediastinum without metastasis tothe regional mediastinum ormetastatic 
foci in the regional or nonregional mediastinum without metastases in 
locoregional nodes. RUL, Right upper lobe; LUL, left upper lobe; RMLL, 
right middle or lower lobe; LLL, left lower lobe. 
patients with nodal micrometastases who had mean 
relapse-free and cancer-related survivals of 18.0 
months and 23.5 months, respectively (p = 0.0157, 
p -- 0.0094). To determine whether the immunohis- 
tochemical documented N stage is an independent 
prognostic factor for relapse-free survival, we per- 
formed a multivariate analysis with a Cox regression 
model. This analysis revealed the independent prog- 
nostic influence on disease-free survival of the pres- 
ence of micrometastases in lymph nodes free of 
metastases according to histopathologic analysis 
(p = 0.011, relative risk 3.1; Table 4). Regarding 
cancer-related survival, multivariate analysis also 
demonstrated an independent prognostic influence 
of the presence of micrometastases (p -- 0.049, 
relative risk 2.9; data not shown). 
Local recurrence-free and distant metastasis-free 
intervals. The mean local recurrence-free interval for 
patients with pN0 tumors without nodal micrometas- 
rases was 47.9 months; that for patients with nodal 
micrometastases was 31.9 months (p = 0.0001). In 
patients with N1 disease without nodal micrometasta- 
ses, the mean local recurrence-free interval was 35.7 
months; that for patients with nodal micrometastases 
was 27.7 months (not significant). 
The mean distant metastasis-free interval for 
patients with NO disease without nodal microme- 
tastases was 45.1 months; that for patients with 
nodal micrometastases was 38.8 months (not sig- 
nificant). In patients with pathologic N1 stage 
disease without nodal micrometastases, the mean 
distant metastasis-free interval was 39.2 months; 
that for patients with nodal micrometastases was 
20.7 months (p = 0.0038). 
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Fig. 2. Relapse-free survival curves among patients with (n = 22) and without (n = 62) micrometastases 
for stage pT1 to pT4 pN0 (p = 0.0081). 
Table III. Effects of micrometastases on survival 
Relapse-free survival Cancer-related survival Local recurrence-free interval 
pN0 (n = 67) 
Without micrometastases (n = 51) 
With micrometastases (n = 16) 
P 
pN1 (n = 17) 
Without micrometastases (n = 11) 
With micrometastases (n = 6) 
P 
Upstaging 
pN2, no micrometastases (n = 36) 
pN0, pN1 with micrometastases (n = 22) 
P 
41.1 44.6 47.9 
29.0 36.5 35.7 
0.0081 0.0584 0.001 
34.8 38.2 31.9 
18.0 23.5 27.7 
0.0157 0.0094 NS 
21.8 
28.6 
NS 
NS, Not significant. 
Extent of nodal micrometastatic involvement and 
prognosis. Among patients with pN0 disease, there 
was no significant correlation between cancer-re- 
lated survival and extent of micrometastatic nodal 
involvement (number of micrometastatic node lev- 
els). Five of 11 patients with only one node level 
involved died of disease (mean survival 33.2 
months) compared with two of five patients with 
more than one level involved who died of disease 
(mean survival 34.8 months, (not significant). Micro- 
metastatic skip nodal involvement had no influence 
on distant metastasis-free interval, local recurrence- 
free interval, relapse-free survival, and overall cancer- 
related survival (data not shown). 
The size of nodal micrometastases (comparison 
between three or fewer disseminated cells and more 
than three cells) showed no statistically significant 
differences with respect o relapse-free and cancer- 
related survivals and distant metastasis-free and 
local recurrence-free intervals. This lack of signifi- 
cant differences indicates that the detection of even 
single epithelial cells is an indicator of disseminated 
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Fig. 3. Cancer-related survival curves for patients with three or fewer disseminated cells (n = 12) and with 
more than three disseminated cells (n = 10, not significant). 
Table IV. Multivariate analysis of relapse-free survival 
Standard Relative risk 
Risk factor Estimated coefficient error p (95% confidence interval) 
pT1 and pT2 vs pT3 and pT4 0.44 0.62 0.476 1.56 (0.46-5.24) 
Adenocarcinoma vs squamous cell carcinoma -0.16 0.40 0.695 0.86 (0.39-1.87) 
pN0 vs pN1 -0.50 0.58 0.383 0.61 (0.20-1.87) 
Immunohistochemical NO vs immunohistochemical N1 and N2 1.15 0.45 0.011 3.14 (1.30-7.62) 
tumor disease. It must be noted, however that the 
numbers in this stratification are rather small 
(Fig. 3). 
Comparison between patients with disease staged 
as NO or N1 with nodal micrometastases and a 
control population of 36 patients with pathohisto- 
logically proved N2 stage disease revealed no statis- 
tical difference in cancer-related survival (Fig. 4). 
The same was true for relapse-free, local recur- 
rence-free, and distant metastasis-free survivals. 
Discuss ion 
The addition of specific immunohistochemical 
assays to the evaluation of lymph nodes in resected 
non-small-cell lung cancer provides an effective tool 
to assess the mode of early mediastinal lymphatic 
spread. In particular, the predominant sites of nodal 
metastases can be identified. 
A nodal micrometastasis was defined as a single 
disseminated cell with positive Ber-Ep4-staining 
within the body of the lymph nodes or clusters of 
such cells up to a size of 2 ram. This classification is
in accordance with the definition given by Attiyeh 
and associates 14 and Huvos, Hutter, and Berg. i5 
Most of these micrometastases, however, are much 
smaller than the limit of 2 mm. In our series, 52% of 
the micrometastases had three or fewer dissemi- 
nated cells, and only one patient showed a micro- 
metastatic lesion of 2 mm. Because no significant 
difference was seen between the incidence of cells 
with positive Ber-Ep-4 staining in patients with 
disease staged as pN0 and those with disease staged 
as pN1, early micrometastatic disease seems to be a 
feature of the continuously developing tumor spread 
and not merely an initiating phenomenon. 
Most tumors exhibited one-level metastases, re- 
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Fig. 4. Cancer-related survival curves for pT1 to pT4 pN0 to pN1 patients with micrometastases (n = 22) 
and patients with pT1 to pT4 pN2 disease (n = 36, not significant). 
gardless of tumor type. In addition, the location of 
the tumor had no influence on the extent of nodal 
spread, nor on the mode of nodal involvement. To 
compare the lymphatic routes with respect to site of 
primary tumor, we divided the mediastinum into 
upper and lower mediastinum to study early lym- 
phatic tumor cell dissemination to the regional and 
nonregional mediastinum. Micrometastatic spread 
in this series also occurred beyond the regional into 
the nonregional mediastinum without involving 
lymph nodes of the regional mediastinum or locore- 
gional nodes. Eight of 17 patients (47%) with upper- 
lobe lesions exhibited skip metastases to the lower 
mediastinum, and five of 12 patients (42%) with 
lower-lobe tumors howed early nodal spread in the 
upper mediastinum. This result is in contrast o 
findings of Watanabe and coworkers 13 and Hata, 
Troidl, and Hasegawa. 16Watanabe 13 reported a 
frequency of skip metastases of 22% from lower- 
lobe lesions to the upper mediastinum and a fre- 
quency of only 8% from upper-lobe tumors to the 
lower mediastinum. Hata, Troidl, and Hasegawa 16
demonstrated by lymphoszintigraphy t at the nor- 
mal lymph drainage is through the regional medias- 
tinum. From the lower lobe, only a small quantity of 
dye reached the upper mediastinal lymph nodes. 
Because of the rather erratic mode of early lym- 
phatic spread, our results upport he recommenda- 
tion for an extensive lymph node sampling in com- 
bination with immunohistochemical studies for 
better postoperative staging. 8
Apart from analyzing patterns of metastatic 
spread, we were interested in the prognostic impact 
of nodal micrometastatic involvement. The presence 
of lymph node metastases in non-small-cell lung 
cancer is of utmost importance toprognosis, t7-19 We 
therefore wanted to know whether micrometastatic 
involvement of lymph nodes exerts influences on 
prognosis and recurrence rate of lung cancer pa- 
tients comparable to those among patients with 
histopathologically positive lymph nodes. In our 
series, 16 of 67 patients in the pN0 group and six of 
17 patients in the pN1 group exhibited negative 
lymph node staging according to conventional his- 
topathologic examination but were positive accord- 
ing to our immunohistochemical assessment. In 
both groups, a significantly decreased recurrence- 
free survival was seen among patients with nodal 
micrometastases. Regarding local recurrence-free 
and distant metastasis-free survival, there was a 
significant advantage for patients with pN0 disease 
without micrometastatic involvement. In contrast, in 
patients with pN1 disease there was a prognostic 
benefit only for the distant metastasis-free interval. 
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Cancer-related survival was also correlated with 
early tumor cell dissemination i  lymph nodes. 
More extensive nodal involvement did not signif- 
icantly decrease survival in the pN0 group; patients 
with involvement of only one level and those with 
involvement of more than one level showed similar 
survivals. The prevalence of skip lesions to medias- 
tinal lymph nodes versus regional mediastinal or 
locoregional lymph node involvement was of no 
prognostic value. In addition, the size of the micro- 
metastases showed no significant influence on sur- 
vival or recurrence. These findings indicate that 
even a single micrometastatic cell is a sufficient 
marker for advanced tumor disease, as we have 
pointed out elsewhere. 7' 2o 
We conclude that the prognosis of patients after 
upstaging of pN0 and pN1 disease according to 
immunohistochemical staining results correlates 
strongly with the prognosis according to conven- 
tional histopathologic examination for these stag- 
es.17-19, 21 Early micrometastatic spread also corre- 
lates with a high rate of recurrent disease in patients 
with pN0 disease. These correlations support our 
view that the current TNM staging system, as pro- 
posed by the International Union Against Cancer in 
1987, 9 should be further refined. Immunohisto- 
chemical assessment of nodal micrometastasis could 
provide such a refinement; however, a consensus 
should be reached regarding the definition (size) of 
nodal micrometastases. 7' 2o 
In conclusion, our results provide a rationale for 
extensive lymph node sampling, enabling us to iden- 
tify the subpopulation of patients with "false nega- 
tive" lymph nodes after standard histopathologic 
examination. In view of the minimal residual tumor 
load, adjuvant therapy might be more effective for 
these patients than for patients with histopatholog- 
ically positive lymph nodes. 
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